Every letter we have printed

Most of the management advice in circulation has no trial behind it and is drawn from clinical experience, which is a legitimate source that should be labelled as one. Your article does label it, and that alone puts it ahead of the material readers usually find. This is not medical advice.

Schedule adjustment is discussed everywhere and studied nowhere, and it interacts directly with the exposure profile in ways the pharmacology department has covered well. The two discussions belong in the same article.

A short note of thanks. I sent this article to two people who needed it and neither has argued with me since.

Excipients determine solution behaviour substantially and are not disclosed on most certificates. Two vials of the same molecule with different buffer systems will not behave alike, and the buyer cannot tell them apart.

The freezer is not a safe default for a solution. Freeze-thaw is among the harsher things you can do to a peptide preparation, and the instinct that colder is always better does real damage here.

The word maintenance carries an assumption that the maintained state is stable. Everything in the published record suggests it is a position held against a gradient, and the vocabulary of maintenance makes the effort involved invisible to people planning around it.

The most useful figure in your maintenance coverage was the proportion who had discontinued by a stated month, printed with the trial and the year. It is a dull number and it puts every other claim in proportion.

The duration after withdrawal is the parameter that determines the headline, and it varies between studies more than any other design feature. A curve measured to week twenty and a curve measured to week eighty tell very different stories about the same phenomenon.

Acute-phase effects move several micronutrient markers independently of status, so a value drawn during any inflammatory episode is difficult to interpret. Measuring an inflammatory marker alongside is standard practice in the literature and rare in self-arranged panels.

Serum concentration and body stores are different quantities for most micronutrients, and the relationship is regulated. A normal serum value is consistent with a range of underlying states, which is why the good assays are the indirect ones.

You describe the low-T3 pattern during energy restriction as benign adaptation. There is a body of opinion holding that it represents a genuine hypometabolic state requiring treatment. I do not hold that view but your readers will encounter it.

Reference change value is the concept that would help most people here, and almost nobody outside laboratory medicine has heard of it. It combines analytical and biological variation into a threshold for a meaningful difference.

The discipline your article recommends is the right one: decide what you would do differently for each result before ordering it. Anything that fails that test is generating a number that will be worried about and not acted on.

Your explanation of endotoxin units is the clearest I have read outside a pharmacopoeia, and the unit is where most confusion starts. A limit expressed per milligram and a limit expressed per container are different constraints, and which one applies depends on how much material is used at once.

Where a supplier does test, ask for the limit against which the result was judged and who set it. A pass against an internally chosen limit is a statement about that limit as much as about the material.

The silence is not a conspiracy. It is what happens when nobody has an obligation, nobody has a question and the instrument that would answer it sits in a different laboratory from the one everybody already uses.

I have worked in aseptic fill for nineteen years and your section on media fills understates one thing. The scale is not the hard part. Running the simulation with every intervention the real process contains — every stopper jam, every environmental sample, every gowning break — is the hard part, and a simulation that omits the interventions is theatre with a growth medium in it.

Your dossier work has shown that suppliers will supply what is asked for individually. That is the strongest evidence that the constraint is demand rather than capability, and it is the more hopeful finding.

Intermittent schedules are being used and are essentially unstudied, and the pharmacokinetics make the reasoning awkward: with a long half-life the concentration does not fall to nothing between doses, so an interrupted schedule is not the same as stopping and restarting.

Whatever pattern somebody follows, recording it makes the difference between an experience and a record. The absence of documented individual patterns is the reason nothing can be learned from a very large amount of use.

Administrative burden is a reason with no name. Reordering, storing, reconstituting, timing — a small load that accumulates, and people stop because it became tiresome rather than because anything went wrong. It is invisible in every dataset because no question asks about it.

A design point rarely made: the withdrawal arm is the only place in this literature where anybody observes what happens after stopping under controlled conditions. However narrow the question, it is the only evidence of its kind and it deserves more careful reading than it gets.

A brief thank you from a reader who works well outside this field and follows it anyway. The writing assumes intelligence without assuming background, which is harder than it looks.

Receptor expression in cardiac tissue is limited and much of the cardiovascular effect is likely indirect. I would rather see that stated as the current reading of the evidence than see the outcome data described as though the mechanism were established.

Receptor distribution maps come largely from tissue studies with antibodies of variable specificity, and several widely reproduced maps rest on reagents that were later questioned. The provenance of a distribution map matters as much as its content.

Exposure varies several-fold between individuals at the same nominal input, which means any statement relating a dose to an effect is a statement about a population average. The variability is published and rarely quoted.

Between-subject variability in exposure is large and rarely mentioned in summaries aimed at general readers. Two people on an identical dose can sit some way apart in plasma concentration, which is a better explanation of divergent experience than most of the ones in circulation.

A short thank you for the reference desk, which I use more often than the articles. Somebody has clearly spent a great deal of time on material that will never be anybody’s headline.

The version I would accept is a mark that renders the determination date, the molecule and the report number in the image, links to the report and greys itself after twelve months. Everything in that list is trivial to build and none of it exists.

I would like badges to carry a date in the image itself, not in a tooltip and not in a linked report. Anything that requires a second click will not be clicked, and a design that depends on diligence the reader does not have is a design that has chosen its outcome.

Publication bias applies here as much as anywhere. A blind programme that publishes only its interesting findings has a denominator problem, and readers have no way to reconstruct the denominator from the outside.

The report format is part of the product and it is priced as though it were not. A one-page summary and a full package with the chromatogram, the suitability data and the audit trail cost the laboratory very different amounts of attention, and most price lists distinguish them by a few pounds.

The retained-sample idea from an earlier letter belongs in this section too. If half the vial stays sealed with the buyer and half goes to the laboratory, a disputed result has a physical answer rather than a rhetorical one.

Our practice for anything contentious is to send two tubes to two laboratories on the same day from the same aliquot. It does not establish custody and it does establish whether the disagreement is about the material or about the method.

Custody matters most exactly when the result is bad, which is when nobody has a record. The discipline has to be in place before it is needed, and the incentive to establish it only appears afterwards.

A modest proposal: publish the shipping cost alongside the result. It sounds irrelevant and it is the fastest way for a reader to tell a genuine retail purchase from a sample that arrived by arrangement.

Your series has not yet addressed what a buyer should do with a single blind result that disagrees with a supplier’s certificate. The honest answer is very little, and saying so would be more useful than another round of methodological argument.

The pieces I have found most useful are the ones that concluded nothing very much. Reporting the absence of a finding is a service and it does not read as one at first.

Your rule about writing down the lower of two orthogonal figures is sound and I would add the corollary. If the two agree within the repeatability of the method, you have learned something real about the material. If they disagree by three points, you have learned something real about at least one of the methods, and that is worth knowing too.

In our hands the useful pairing is a hydrophobicity separation for the bulk figure and a charge-based one for the degradation question. They answer different questions and we stopped pretending either was a check on the other. Once we said that out loud the reporting became much simpler.